GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Polynovo Ltd (FRA:MFJ) » Definitions » EV-to-Revenue

Polynovo (FRA:MFJ) EV-to-Revenue : 16.76 (As of Apr. 26, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Polynovo EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Polynovo's enterprise value is €857.57 Mil. Polynovo's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was €51.16 Mil. Therefore, Polynovo's EV-to-Revenue for today is 16.76.

The historical rank and industry rank for Polynovo's EV-to-Revenue or its related term are showing as below:

FRA:MFJ' s EV-to-Revenue Range Over the Past 10 Years
Min: 11.28   Med: 59.39   Max: 249.32
Current: 17.12

During the past 13 years, the highest EV-to-Revenue of Polynovo was 249.32. The lowest was 11.28. And the median was 59.39.

FRA:MFJ's EV-to-Revenue is ranked worse than
88.36% of 825 companies
in the Medical Devices & Instruments industry
Industry Median: 3.07 vs FRA:MFJ: 17.12

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-04-26), Polynovo's stock price is €1.24. Polynovo's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was €0.07. Therefore, Polynovo's PS Ratio for today is 16.76.


Polynovo EV-to-Revenue Historical Data

The historical data trend for Polynovo's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Polynovo EV-to-Revenue Chart

Polynovo Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 75.22 75.71 64.04 21.75 15.87

Polynovo Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 21.75 - 15.87 -

Competitive Comparison of Polynovo's EV-to-Revenue

For the Medical Devices subindustry, Polynovo's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Polynovo's EV-to-Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Polynovo's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Polynovo's EV-to-Revenue falls into.



Polynovo EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Polynovo's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=857.568/51.163
=16.76

Polynovo's current Enterprise Value is €857.57 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Polynovo's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was €51.16 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Polynovo  (FRA:MFJ) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Polynovo's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=1.24/0.074
=16.76

Polynovo's share price for today is €1.24.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2023 was €0.07.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Polynovo EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Polynovo's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Polynovo (FRA:MFJ) Business Description

Traded in Other Exchanges
Address
320 Lorimer Street, Unit 2, Port Melbourne, VIC, AUS, 3207
Polynovo earns most of its revenue from U.S. sales of its NovoSorb Biodegradable Temporizing Matrix, or NovoSorb BTM. The product is a patented biodegradable synthetic scaffold to support the regeneration of the dermis when lost through surgery, trauma, burns, or other causes of tissue loss. Once the product is applied to a wound, it takes a few weeks for the dermal layer to fully integrate within the polymer scaffold before a clinician can delaminate the outer layer. A small wound would then close either naturally or with a dressing, while a larger wound would close through a split-skin graft or alternative product such as Avita's RECELL. NovoSorb BTM then slowly degrades to harmless byproducts which are fully absorbed in roughly 18 months.

Polynovo (FRA:MFJ) Headlines

No Headlines